Citigroup’s Avalyn Pharma AVLN Stock Holding History

Citigroup’s Portfolio AVLN Stock Details AVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$265K	Buy	+8,035	New	+$232K	﹤0.01%	4204

Other funds holding AVLN

Andera Partners Paris $206M AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

SCM

Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

Citigroup's AVLN Position: Q2 2026 in Review

Citigroup opened a new position in Avalyn Pharma (AVLN) in Q2 2026: 8,035 shares worth $265K. The stake represents ﹤0.01% of the portfolio and ranks #4204 among its holdings.

11 funds tracked by Wall St. Rank hold AVLN as of Q2 2026.

Citigroup held 8,035 shares of Avalyn Pharma worth $265K as of Q2 2026.
Avalyn Pharma was a new Citigroup position in Q2 2026.
Avalyn Pharma made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4204 holding.
11 funds tracked by Wall St. Rank held Avalyn Pharma as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.